Dianthus Therapeutics (DNTH) Q1 2026 earnings summary

Executive summary

• Focused on developing therapies for severe autoimmune diseases, with lead candidates claseprubart and DNTH212 in mid- to late-stage clinical trials for multiple indications, including gMG, CIDP, and MMN.

• Early GO decision in CAPTIVATE Phase 3 trial for claseprubart in CIDP after 20 confirmed responders, ahead of schedule.

• Claseprubart granted Orphan Drug Designation by FDA for Myasthenia Gravis in May 2026.

• Phase 3 gMG trial for claseprubart to start mid-2026, with top-line results expected in 2H 2028; CAPTIVATE Part B (CIDP) top-line guidance by end of 2026.

• DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor, entered Phase 1 in late 2025, targeting multiple autoimmune indications; Phase 1 data in healthy volunteers anticipated 2H 2026.

Financial highlights

• Cash, cash equivalents, and investments totaled $1.2 billion as of March 31, 2026, providing expected runway into 2030.

• License revenue was $0.5 million for Q1 2026, down from $1.2 million in Q1 2025, due to lower reimbursable costs.

• Research and development expenses rose to $34.5 million (Q1 2026) from $27.0 million (Q1 2025), driven by increased clinical activity and personnel.

• General and administrative expenses increased to $12.5 million from $7.3 million year-over-year, mainly due to higher stock-based compensation and headcount.

• Net loss for Q1 2026 was $40.8 million ($0.85 per share), compared to $29.5 million ($0.82 per share) in Q1 2025.

Outlook and guidance

• Existing cash and investments expected to fund operations into 2030.

• Anticipates continued increases in R&D and G&A expenses as clinical programs advance.

• Phase 3 EMERGE trial in gMG to initiate mid-2026; top-line results expected 2H 2028.

• CAPTIVATE Part B (CIDP) top-line guidance expected by year-end 2026.

• DNTH212 Phase 1 top-line results in healthy volunteers expected in H2 2026.